Breaking News

Wednesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
TDOC Teladoc $62.20 -3 (-4.60%) , UNH UnitedHealth $255.52 1.84 (0.73%) 07:55 07/11/18 07/11 07:55 07/11/18 07:55 Recommendations	Teladoc, UnitedHealth analyst commentary at Jefferies » Teladoc price target… Teladoc price target raised to $74 from $49 at Jefferies. Jefferies analyst Sean Dodge raised his price target for Teladoc (TDOC) to $74 saying he' "increasingly bullish" following meetings with management. The company's new "Surround Sound" member engagement strategy continues to drive utilization improvements, Dodge tells investors in a research note. Further, the analyst sees potential upside from Teladoc's relationship with UnitedHealth (UNH), which he believes it "set to blossom." Dodge keeps a Buy rating on Teladoc shares. TDOC Teladoc $62.20 -3 (-4.60%) UNH UnitedHealth $255.52 1.84 (0.73%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Jul
AAPL Apple $190.40 -0.25 (-0.13%) , PG Procter & Gamble $79.83 1.96 (2.52%) … 07:30 07/11/18 07/11 07:30 07/11/18 07:30 Options	Unusual put flow in option market yesterday » Notable put activity was… Notable put activity was cited Tuesday in Apple (AAPL), Procter & Gamble (PG), Pandora (P), and Teladoc (TDOC). AAPL Apple $190.40 -0.25 (-0.13%) PG Procter & Gamble $79.83 1.96 (2.52%) P Pandora $7.72 -0.27 (-3.38%) TDOC Teladoc $62.20 -3 (-4.60%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	31 Jul

Tuesday
TDOC Teladoc $62.65 -2.55 (-3.91%) 13:10 07/10/18 07/10 13:10 07/10/18 13:10 Options	Defensive optoin play in Teladoc as shares move off all-time highs » Defensive optoin play in… Defensive optoin play in Teladoc as shares move off all-time highs. The stock has surrendered morning gains and is off $2.05 to $63.10. In recent option action, 2.3K Aug 70 calls trade at $1.90 along with 2.3K Aug 55 - 60 put spreads for $1.70. The strategy is likely short calls along with a vertical put spread, or a short-term hedge after recent gains, as the stock is up 80% YTD and earnings are due in a few weeks. The three-way will create the largest open interest blocks in the name, which has just 15K open across all strikes. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
TDOC Teladoc $63.35 0.55 (0.88%) 07:34 07/09/18 07/09 07:34 07/09/18 07:34 Recommendations	Teladoc analyst commentary at KeyBanc » Teladoc price target… Teladoc price target raised to $70 from $50 at KeyBanc. KeyBanc analyst Donald Hooker raised his price target for Teladoc to $70 from $50 looking into 2H18 and following the acquisition of Advance Medical. The analyst reiterates an Overweight rating on the shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $63.35 0.55 (0.88%) 06:36 07/09/18 07/09 06:36 07/09/18 06:36 Initiation	Teladoc initiated at Berenberg » Teladoc initiated with a… Teladoc initiated with a Buy at Berenberg. Berenberg analyst Robert Lamb initiated Teladoc with a Buy and $72 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
TDOC Teladoc $54.25 0.45 (0.84%) 07:29 06/07/18 06/07 07:29 06/07/18 07:29 Recommendations	Teladoc analyst commentary at Deutsche Bank » Teladoc price target… Teladoc price target raised to $56 from $45 at Deutsche Bank. Deutsche Bank analyst Glen Santangelo raised his price target for Hold-rated Teladoc to $56 to reflect the acquisition of Advance Medical. The analyst expects Advance Medical's revenue growth rate to gradually increase as it leverages Teladoc's infrastructure and marketing potential. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Jun
TDOC Teladoc $51.85 1.1 (2.17%) 09:00 06/05/18 06/05 09:00 06/05/18 09:00 Upgrade	Teladoc rating change » Teladoc upgraded to Buy… Teladoc upgraded to Buy at Craig-Hallum. As previously reported, Craig-Hallum analyst Matt Hewitt upgraded Teladoc to Buy from Hold saying the Advance Medical acquisition provides jumpstart to international expansion. The analyst also raised his price target on the shares to $60 from $39. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Jun 12 Jun
TDOC Teladoc $51.85 1.1 (2.17%) 07:42 06/05/18 06/05 07:42 06/05/18 07:42 Upgrade	Teladoc rating change at Craig-Hallum » Teladoc upgraded to Buy… Teladoc upgraded to Buy from Hold at Craig-Hallum 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Jun 12 Jun
TDOC Teladoc $51.85 1.1 (2.17%) 07:32 06/05/18 06/05 07:32 06/05/18 07:32 Recommendations	Teladoc analyst commentary at Citi » Teladoc price target… Teladoc price target raised to $62 from $51 at Citi. Citi analyst Stephanie Demko raised her price target for Teladoc to $62 and reiterates a Buy rating on the shares following the company's acquisition of Advance Medical. The analyst views the purchase price as reasonable. The acquisition makes Teladoc the sole global telehealth player while also expanding the company's telehealth solution suite into home care, wellness, and chronic care, Demko investors in a research note. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Jun 12 Jun
TDOC Teladoc $51.85 1.1 (2.17%) 07:23 06/05/18 06/05 07:23 06/05/18 07:23 Recommendations	Teladoc analyst commentary at Cantor Fitzgerald » Teladoc price target… Teladoc price target raised to $50 from $35 at Cantor Fitzgerald. Cantor Fitzgerald analyst Steven Halper raised his price target for Teladoc to $50 saying the acquisition of Advance Medical appears "logical both strategically and financially." The analyst keeps a Neutral rating on the shares due to valuation. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Jun 12 Jun

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial